Completed study
Official Study Title
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019 (COVID-19): A randomized controlled trial (FERMIN trial)
Brief Description
FERMIN is a randomized clinical trial aiming to assess the clinical impact of fenofibrate to improve clinical outcomes in patients with COVID-19.
Details
Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 8 sites in Greece
Actual enrolment: 200 participants
EudraCT number: 2021-000843-33
National Organization for Medicines Approval: IS026-21
National Ethics Committee Approval: 20/21
Study Start: April 2021
Study Completion: April 2022
Condition/Disease studied: COVID-19
Keywords: COVID-19
Related publications
- A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019
Nature Metabolism 2022 Nov 7;1–11